ICS 2015 Scientific Podium Short Oral Session S10 - Updates on the Use of Botulinum Toxin

Updates on the Use of Botulinum Toxin

Speakers
	Scientific Podium Short Oral Session S10
	Wednesday 7th October 2015
	14:00 - 15:30
	210AE
	Lunch provided
J Jacques Corcos ICS Chair U Ulrich Mehnert ICS Chair
Learning Objectives
To examine novel research findings in the field of Updates on the Use of Botulinum Toxin. To discuss methodological challenges for conducting research in the field of Updates on the Use of Botulinum Toxin. To discern the internal and external generalizability of these research results in order to implement changes in research methods or clinical practice within the participant's own setting.

Session Schedule

14:00

#163 ALKALINISED LIDOCAINE VERSUS LIDOCAINE GEL AS LOCAL ANAESTHESIA PRIOR TO INTRA-VESICAL BOTULINUM TOXIN (BoNTA) INJECTIONS: A PROSPECTIVE, SINGLE CENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP TRIAL OF EFFICACY AND MORBIDITY

Presenter: Arjun Nambiar

Nambiar A¹, Younis A², Khan Z³, Hildrup I⁴, Emery S³, Lucas M¹
1. Morriston Hospital, ABMU LHB, Swansea, UK, 2. Freeman Hospital, Newcastle-upon-Tyne NHS trust, 3. Singleton Hospital, ABMU LHB, Swansea, UK, 4. Clinical Research Unit, ABMU LHB, Swansea, UK
Clinical Trial, Pain, other, Overactive Bladder, Pharmacology, Incontinence

14:07

#164 Adverse Events with Botox and Dysport for refractory overactive bladder: A systematic review

Presenter: Arun Sahai

Eldred-Evans D¹, Seth J¹, Khan M S¹, Chapple C², Dasgupta P¹, Sahai A¹
1. Guy's and St. Thomas' Hospital, 2. Sheffield Teaching Hospitals NHS Foundation Trust
Overactive Bladder, Outcomes Research Methods, Urgency/Frequency

14:15

#165 OnabotulinumtoxinA Reduces Nocturnal Voids and Improves Quality of Life in Overactive Bladder Patients with Nocturia

Presenter: Roger Dmochowski

Dmochowski R¹, Ginsberg D², Parsons M³, Robinson D⁴, Magyar A⁵, Nicandro J⁶, Drake M⁷
1. Vanderbilt University Medical Center, Nashville, TN, USA, 2. USC Institute of Urology, Los Angeles, CA, USA, 3. Birmingham Women's NHS Foundation, Edgbaston, Birmingham, UK, 4. King's College Hospital NHS Foundation, London, UK, 5. Allergan, Inc, Bridgewater, NJ, USA, 6. Allergan, Inc, Irvine, CA, USA, 7. Bristol Urological Institute, Bristol, UK
Overactive Bladder, Detrusor Overactivity, Quality of Life (QoL)

14:22

#166 Clinically Meaningful Improvements in Urinary Incontinence Following Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study

Presenter: Sidney Radomski

Radomski S¹, Ginsberg D², Chapple C³, Sussman D⁴, Sand P⁵, Sievert K⁶, De Ridder D⁷, Jenkins B⁸, Zheng Y⁸, Nitti V⁹
1. University of Toronto, 2. University of Southern California, 3. Sheffield Teaching Hospital, 4. Rowan University, 5. Evanston Continence Center, 6. University of Luebeck, 7. University Hospitals KU Leuven, 8. Allergan, Inc., 9. New York University Langone Medical Center
Overactive Bladder, Incontinence, Detrusor Overactivity, Clinical Trial

14:30

#167 OnabotulinumtoxinA Significantly Improves Urinary Incontinence and Quality of Life in Overactive Bladder Patients Regardless of Incontinence Severity at Baseline

Presenter: Sender Herschorn

Ginsberg D¹, Gruenenfelder J², Moore C³, Kaufmann A⁴, Drake M⁵, Joshi M⁶, Magyar A⁷, Herschorn S⁸
1. USC Institute of Urology, Los Angeles, CA, USA, 2. Orange County Urology Associates, Laguna Hills, CA, USA, 3. Cleveland Clinic, Cleveland, OH, USA, 4. Kliniken Maria Hilf GmbH, Mönchengladbach, Germany, 5. Bristol Urological Institute, Bristol, UK, 6. Allergan, Inc, Irvine, CA, USA, 7. Allergan, Inc, Bridgewater, NJ, USA, 8. University of Toronto, Toronto, ON, Canada
Overactive Bladder, Incontinence, Quality of Life (QoL)

14:37

#168 Safety and Efficacy of OnabotulinumtoxinA for the treatment of neurogenic and idiopathic overactive bladder: A meta-analysis of ten randomized controlled trials

Presenter: Omar Naser

Naser O¹, Mohamed O², Zein H², Hassan O², Kamel M³, Al Nahrawi S⁴, Negida A², Ali W⁵, Omar A⁶, Ashraf B², Gana B¹
1. West Wales general hospital, Carmarthen, UK, 2. Faculty of medicine, Zagazig University, Egypt, 3. Faculty of medicine, Al Azhar University, Cairo, Egypt, 4. Faculty of medicine, Tanta University, Egypt, 5. Faculty of Medicine, Misr University For Science and Technology, Egypt, 6. Faculty of Medicine, Cairo University, Egypt
Urgency Urinary Incontinence, Overactive Bladder, Detrusor Overactivity, Urgency/Frequency

14:45

#169 OnabotulinumtoxinA injections for idiopathic and neurogenic overactive bladder: discontinuation rates and reasons for treatment disruption

Presenter: Salvador Arlandis Guzman

Arlandis Guzman S¹, López-Fando Lavalle L², Gallego A¹, Fabuel Alcañiz J J², Broseta E¹, Jiménez-Cidre M A²
1. HUP La Fe, 2. H Ramón y Cajal
Overactive Bladder, Urgency Urinary Incontinence, Pharmacology

14:52

#170 Onabotulinumtoxin A Improves Quality of Life in Patients with Indwelling Catheters

Presenter: Kevin Carlson

Carlson K¹, Civitarese A², Weber B¹, Desantis D¹, Crump T², Baverstock R¹
1. vesia Alberta Bladder Centre, University of Calgary Dept. of Surgery, 2. vesia Alberta Bladder Centre
Quality of Life (QoL), Incontinence, Prospective Study, Detrusor Overactivity, Multiple Sclerosis

15:00

#171 Predictors of Adverse Events after OnabotulinumtoxinA Treatment for Patients with Overactive Bladder Syndrome

Presenter: Hueih-Ling Ong

Ong H¹, Jiang Y¹, Kuo H¹
1. Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan
Detrusor Overactivity, Pharmacology, Quality of Life (QoL)

15:07

#172 Less Is More – A New Intradetrusor Onabotulinumtoxin A Injection Technique for Neurogenic and Idiopathic Detrusor Overactivity

Presenter: R Corey O'Connor

O'Connor R C¹, Sack B¹, Guralnick M¹
1. Medical College of Wisconsin
Detrusor Overactivity, Overactive Bladder, Incontinence, Neuromodulation, Questionnaire

15:15

#173 Intradetrusor Botulinum Toxin Injections for the Management of Anticholinergic Refractory, Poorly Compliant Neurogenic Bladders

Presenter: Michael Guralnick

Johnson D¹, Guralnick M¹, O'Connor R C¹
1. Medical College of Wisconsin
Neuromodulation, Spinal Cord Injury, Retrospective Study

15:22

#174 Higher Neural Correlates Following Intravesical Botulinum Toxin- A in Multiple Sclerosis (MS) Patients via Concurrent Functional Magnetic Resonance Imaging (fMRI) and Urodynamic Studies (UDS)

Presenter: Rose Khavari

Khavari R¹, Shy M², Karmonik C¹, Anderson J¹, Boone T¹
1. Houston Methodist Hospital, 2. Baylor College of Medicine
Anatomy, Multiple Sclerosis, Detrusor Overactivity, Imaging

International Continence Society

Updates on the Use of Botulinum Toxin

Session Schedule

Comments

Chat